Search | Clinical Trials Finder

Conditions: Influenza (Healthy Volunteers)
Interventions: Exposure to Donors with naturally acquired influenza virus infection; Other
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Pandemic Influenza Immunization, Healthy Volunteers
Interventions: Pandemic flu H5 HA mRNA SD2 vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Trivalent Influenza Vaccine; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 40 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy Participants
Interventions: Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 37
States / cities: Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: MK-1406 Injection; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 66 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Miami Lakes, Florida • Spartanburg, South Carolina

Conditions: Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions: Live recombinantly derived A/Bethesda/MM1/H3N2 virus; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza, Human
Interventions: VRC-FLUDNA056-00VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 45 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Annandale, Virginia

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Influenza
Interventions: AVX502, Placebo; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Influenza
Interventions: AVI-7100, Placebo; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska

Conditions: Influenza
Interventions: Peramivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteer
Interventions: Ad4-H5-Vtn; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Flucelvax(R), Human Challenge virus; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Ca/04/2009/H1N1 Vero Grown Challenge Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A Virus, H1N1 Subtype
Interventions: Zanamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza
Interventions: Flufirvitide 3, Placebo for Flufirvitide-3; Drug
Lead sponsor: Autoimmune Technologies, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: H5N1 Influenza
Interventions: Ad4-H5-VTN vaccination-tonsillar route, Ad4-H5-vaccination-oral route; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy, no Evidence of Disease
Interventions: cholecalciferol, questionnaire administration, trivalent influenza vaccine; Dietary Supplement · Other · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Influenza
Interventions: Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012); Biological
Lead sponsor: PowderMed; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Lenexa, Kansas • Springfield, Missouri

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 3 more

Search by objective public record fields.

Evaluating Modes of Influenza Transmission 2b Baseline SAR

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

Safety Study of Single Administration Intravenous Treatment for Influenza

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

Safety and Dose Study of Peramivir for Influenza Treatment

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route

Influenza A 2009 H1N1 Challenge Study in Healthy Adults

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older